Navigation Links
Novel Liver Stem Cell Model Could Speed Up Process for Developing New Drugs
Date:6/11/2013

Durham, NC (PRWEB) June 11, 2013

The path to bringing a new drug to market is, simply put, a rocky one. Not only is it estimated to take over 12 years at an average price tag running anywhere between US $800 million and US $2 billion, but more often than not the new drug never makes it through the process.

But now a research team reports that it has developed a way to speed up the process. Their work, which involves the creation of a highly stable and sensitive liver stem cell model, is reported in the latest issue of STEM CELLS Translational Medicine.

“Liver toxicity is the second most common cause of human drug failure,” explained David Hay, Ph.D., of the University of Edinburgh’s MRC Centre for Regenerative Medicine, who led the team made up of university colleagues and scientists from Bristol-Myers Squibb, Princeton, N.J. “But one major bottleneck in safety testing new drugs has been finding a routine supply of good quality primary human hepatocytes from the desired genetic background.”

Scientists have long believed that finding an efficient way to force pluripotent stem cells (PSCs) to develop into hepatocytes — liver cells — could be the way around the problem. “But faithfully recapitulating human physiology in a dish from a renewable source remains a holy grail for medicine and the pharmaceutical industry,” Dr. Hay noted.

“Many procedures have been described that, to a limited extent, exhibit human-tissue-specific function in vitro but incomplete cellular differentiation and/or the loss of cell phenotype after they differentiate. Using our knowledge in pharmacology, stem cell biology and materials chemistry, we developed a highly stable and sensitive model.”

Their method involved expanding PSCs and driving their differentiation to hepatocytes, then replating them onto a synthetic surface. The results yielded active cell populations that displayed stable function for over two weeks in vitro.

“The scalable nature of our model combined with the interchangeable genetic element demonstrates clear advantages over the erratic supply of highly variable human hepatocytes from deceased specimens,” Dr. Hay added. “We believe our approach is important and will likely contribute to improvements in drug safety testing.”

“This model was compared to human liver cells from deceased donors and found to be equivalent, suggesting that stem cell-derived hepatocyles have potential to improve the preclinical assessment of human liver toxicity,” said Anthony Atala, M.D., Editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. “

The full article, “Developing high fidelity hepatotoxicity models from pluripotent stem cells,” can be accessed at http://www.stemcellstm.com.

About STEM CELLS Translational Medicine: STEM CELLS TRANSLATIONAL MEDICINE (SCTM), published by AlphaMed Press, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals: STEM CELLS® (http://www.StemCells.com), celebrating its 31st anniversary in 2013, is the world's first journal devoted to this fast paced field of research. The Oncologist® (http://www.TheOncologist.com), also a monthly peer-reviewed publication, entering its 18th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.

Read the full story at http://www.prweb.com/releases/2013/6/prweb10819762.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Surgeons Complete Clinical Trial on Novel Two-Part Heart Valve
2. New research findings on onset of uterine fibroids provide potential for novel treatments
3. Researchers identify novel approach to create red blood cells, platelets in vitro
4. Discovery of a novel medicine for the treatment of chronic wounds
5. Columbia licenses novel 3-D organ and tumor segmentation software to Varian Medical Systems
6. PolyU Researchers Develop Novel Brain Training Device to Reconnect the Brain and Paralyzed Limb After Stroke
7. Novel study reports marijuana users have better blood sugar control
8. Teen Struggles Through Drug Treatment in Paddy Stewart’s New Novel
9. Expert Panel to Discuss Perspectives on Evaluating Novel Diagnostics for Reimbursement at 2013 Next Generation Dx Summit In Washington, DC
10. Novel Drug Treatment Quickly Reverses Traumatic Brain Injury
11. Novel Drug Treatment Quickly Reverses Alzheimer’s Disease Resulting in a Significant Reduction in Assisted Living Expenses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... Mirror Mirror Beauty Boutique ... Look Awesome This Autumn with CoolSculpting®. Scheduled for Thursday, September 28th, the afternoon ... Mirror Mirror Beauty Boutique is Houston’s largest CoolSculpting provider, holding the ...
(Date:9/20/2017)... ... 20, 2017 , ... Announced that Clear Global ... services market) has entered into an agreement on September 1, 2017 with The ... is the first private Dental School to launch an online, accredited Post Graduate ...
(Date:9/20/2017)... ... September 20, 2017 , ... Compliancy Group ... compliance software, The Guard®, has helped another long-time client pass their Department of ... properly satisfy the law. , Thanks to the help of the Compliancy Group's ...
(Date:9/20/2017)... ... ... In just a short time since going on sale on Wal-Mart Stores-owned ... trying the product for the first time, and others who had already been using ... Moore, MD, for everyone from athletes at risk from multiple concussions to elderly consumers ...
(Date:9/20/2017)... ... September 20, 2017 , ... Five consumer packaged goods (CPG) products were selected ... different categories. Nopavera Plus was named to the short list in the ... West 2017 during presentations at SupplySide Central on Sept. 27 and 28 at Mandalay ...
Breaking Medicine News(10 mins):
(Date:9/1/2017)... Michael Penna , President and CEO ... for growth in his response to the July 13, ... seeking a buyer for eMDs. Penna,s company, Complete HealthCare ... Value Added Reseller and national leader in the independent ... "As the healthcare market continues to dictate consolidation, healthcare ...
(Date:8/29/2017)... ivWatch, LLC, the leading provider of continuous monitoring devices for the ... an Innovative Technology contract from Vizient, Inc., the largest member-driven health ... ... detection of peripheral IV infiltration and extravasation events ... The Innovative Technology contract was awarded to ivWatch based on ...
(Date:8/25/2017)... 2017  Innovation Zed ( www.innovationzed.com ), an Irish medtech company, today ... South Yorkshire and Bassetlaw, England . ... diabetes patients as part of a national NHS Test Bed programme exploring ... Innovation Zed ... InsulCheck Connect, a snap-on accessory for disposable insulin pen users, ...
Breaking Medicine Technology: